Jun O. Liu

A zebrafish phenotypic drug screen identifies 49 ApoB-lowering compounds, with enoxolone showing efficacy dependent on HNF4 function, validating the LipoGlo platform for B-lp modulation.

This paper identifies triptolide as a compound that enhances the effectiveness of DNMTi by inhibiting DCTPP1, overcoming resistance in cancer cells.

This study identifies P-glycoprotein as a mediator of Rapaprotin resistance and shows that co-treatment with tariquidar restores its efficacy in colorectal cancer cells.

This paper identifies rapaglutin E as a specific inhibitor of GLUT1 and explores its binding mechanism compared to rapaglutin A.

This paper identifies rapaprotin as a 26S proteasome assembly inhibitor that is activated by PREP to induce apoptosis and synergizes with proteasome inhibitors in cancer cells.

The paper develops a CaMKII biosensor for high-throughput screening and identifies ruxolitinib as a potent and cardioprotective CaMKII inhibitor effective in preventing atrial fibrillation.

The paper identifies neuroprotective compounds for retinitis pigmentosa using cross-species drug screens in zebrafish and mouse models, finding additive effects in some combinations.

This study evolves resistance to GAPDH inhibition and shows that cells lose the Warburg Effect but maintain a distinct glycolytic state with different metabolic dependencies.